

# Human in vitro liver metabolism using HLM, HLCYT and Liquid Chromatography coupled to High-Resolution Mass Spectrometry

Created on: 04-10-2019 - Last modified on: 08-11-2019

## **Contact person**

Philippe Vervliet

# **Organisation**

Name of the organisation University of Antwerp (UAntwerpen)

**Department** Department of Pharmaceutical Sciences

**Country** Belgium

Geographical Area Flemish Region

#### SCOPE OF THE METHOD

The Method relates to	Environment, Human health
The Method is situated in	Basic Research
Type of method	In vitro - Ex vivo
Specify the type of cells/tissues/organs	Human Liver Microsomes and Human Liver Cytosol

### **DESCRIPTION**

## **Method keywords**

HLM

**HLCYT** 

Liquid chromatography

mass spectrometry

Metabolism

liver

in vitro

### Scientific area keywords

Toxicology

analytical chemistry

liver metabolism

Drug metabolism

Drug discovery

#### **Method description**

A compound of interest (e.g. new psychoactive substance, endocrine disrupting compound, ...) is incubated with human liver microsomes and liver cytosolic fractions to generate both Phase I and II metabolites. Samples are prepared for analysis using a simple method in order to avoid possible losses of biotransformation products. The extracts are analysed using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. Identification of the biotransformation products is performed using complementary screening workflows. These include a suspect screening based on *in silico* predictions and non-targeted screening using either vendor-specific or in-house developed open-source software protocols.

# Lab equipment

- Warm water bath (37°C);
- Temperature-controlled nitrogen evaporator;
- Centrifuge ;
- LC coupled to high-resolution mass spectrometry (for identification).

#### **Method status**

Published in peer reviewed journal

# PROS, CONS & FUTURE POTENTIAL

#### **Advantages**

- Optimized assay with different timepoints, negative and positive controls and method blanks;
- Tested for a variety of substrates (NPSs, EDCs, ...) resulting in multiple publications;
- Custom data analysis possible, according to research question;
- Besides analytical equipment (LC-HRMS) no need for expensive equipment.

#### Challenges

- Possible over or underestimation of *in vivo* biotransformation;
- Suspect screening dependent on strength of *in silico* predictions.

#### **Modifications**

- No further optimizations are planned for the near future.

#### REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION

#### **Associated documents**

2018 - Vervliet Mortele et al - DTA - 5CI-THJ-018.pdf







